Ligand Pharmaceuticals Inc (LGND)

Finanzdaten der Ligand Pharmaceuticals Inc-Aktie (LGND)

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2026-09-30	2026-06-30	2026-03-31	2025-12-31	2025-09-30
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	23.63%78.75	63.69	51.72	59.67	115.46
	81.14%2.77	14.67	2.15	-	-
Research and Development	81.14%2.77	14.67	2.15	-	-
Operating Income/Loss	283.42%-15.76	8.59	17.37	13.84	54.93
Nonoperating Income/Loss	150.86%-28.34	55.71	-41.63	42.94	86.21
Income/Loss From Continuing Operations Before Tax	168.57%-44.09	64.30	-24.26	56.78	141.14
Income Tax Expense/Benefit	198.82%-15.61	15.80	-10.91	12.00	23.86
	158.72%-28.49	48.51	-13.35	44.78	117.27
Attributable To Parent	158.72%-28.49	48.51	-13.35	44.78	117.27
Basic Average Shares	0.50%19.96	20.06	19.88	-0.03	19.58
Diluted Average Shares	8.59%19.96	21.84	19.88	0.12	20.63
Basic Earnings Per Share	159.09%-1.43	2.42	-0.67	2.33	5.99
Diluted Earnings Per Share	164.41%-1.43	2.22	-0.67	2.18	5.68